Breast Cancer—Benefits of ZOL Are Beyond Those of PAM and Continue After the Onset of SREs Risk reduction Relative risk In favor of zoledronic acid In favor of pamidronate 00.2 0.40.60.811.21.41.61.82 P value All SREs (n = 766).015 0.711 29%.045 0.690 31% Excluding first SRE ZOL reduced the risk of experiencing any SRE on study or after the first SRE by ~30% vs PAM a in a large, double-blind, phase III trial a As determined by Andersen-Gill multiple event analysis.